215 related articles for article (PubMed ID: 31760930)
1. Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Fu X; Li YS; Zhao J; Yu LL; Luo RG; Liang QR; Tang Q
Mini Rev Med Chem; 2020; 20(3):239-251. PubMed ID: 31760930
[TBL] [Abstract][Full Text] [Related]
2. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases.
Wang QQ; Jiang Y; Naranmandura H
Metallomics; 2020 Mar; 12(3):326-336. PubMed ID: 32163072
[TBL] [Abstract][Full Text] [Related]
5. Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review.
Fei W; Li C; Tao J; Cai X; Yao W; Ye Y; Zhang Y; Yao Y; Song Q; Li F; Zheng C
Int J Pharm; 2020 Jun; 583():119385. PubMed ID: 32376447
[TBL] [Abstract][Full Text] [Related]
6. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
7. In the war against solid tumors arsenic trioxide needs partners.
Subbarayan PR; Ardalan B
J Gastrointest Cancer; 2014 Sep; 45(3):363-71. PubMed ID: 24825822
[TBL] [Abstract][Full Text] [Related]
8. Angiopep-2-Conjugated "Core-Shell" Hybrid Nanovehicles for Targeted and pH-Triggered Delivery of Arsenic Trioxide into Glioma.
Tao J; Fei W; Tang H; Li C; Mu C; Zheng H; Li F; Zhu Z
Mol Pharm; 2019 Feb; 16(2):786-797. PubMed ID: 30620881
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
[No Abstract] [Full Text] [Related]
10. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
Sönksen M; Kerl K; Bunzen H
Med Res Rev; 2022 Jan; 42(1):374-398. PubMed ID: 34309879
[TBL] [Abstract][Full Text] [Related]
11. A candidate for lung cancer treatment: arsenic trioxide.
Huang W; Zeng YC
Clin Transl Oncol; 2019 Sep; 21(9):1115-1126. PubMed ID: 30756240
[TBL] [Abstract][Full Text] [Related]
12. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.
Kong D; Jiang T; Liu J; Jiang X; Liu B; Lou C; Zhao B; Carroll SL; Feng G
Drug Deliv; 2020 Nov; 27(1):1729-1740. PubMed ID: 33307843
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia.
Gao C; Hu S; Guo M; Hai X; Zhou J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):229-236. PubMed ID: 29845392
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide-loaded CalliSpheres:
Duan X; Zhao G; Han X; Ren J; Li H; Chen P; Wang M; Ju S
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 33982781
[TBL] [Abstract][Full Text] [Related]
15. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide in pediatric cancer - a case series and review of literature.
Abele M; Müller SL; Schleicher S; Hartmann U; Döring M; Queudeville M; Lang P; Handgretinger R; Ebinger M
Pediatr Hematol Oncol; 2021 Aug; 38(5):471-485. PubMed ID: 33635158
[TBL] [Abstract][Full Text] [Related]
17. Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide.
Wahiduzzaman M; Ota A; Hosokawa Y
Curr Cancer Drug Targets; 2020; 20(2):115-129. PubMed ID: 31736446
[TBL] [Abstract][Full Text] [Related]
18. Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Grimm S; Fayter D; Deshpande S; Armstrong N; Witlox W; Pouwels X; Duffy S; Worthy G; Kleijnen J; Joore MA
Pharmacoeconomics; 2019 Jul; 37(7):887-894. PubMed ID: 30426463
[TBL] [Abstract][Full Text] [Related]
19. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
[TBL] [Abstract][Full Text] [Related]
20. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
